Prognostic significance of the Ki67 scoring categories in breast cancer subgroups

Naoki Niikura, Shinobu Masuda, Nobue Kumaki, Tang Xiaoyan, Mizuho Terada, Mayako Terao, Takayuki Iwamoto, Risa Oshitanai, Toru Morioka, Banri Tuda, Takuho Okamura, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Our data demonstrated that Ki67 scores have a prognostic value in breast cancer patients with ERpositive and HER2-negative tumors. Background: Immunohistochemical (IHC) expression of Ki67 has a prognostic and predictive value for breast cancer, and the IHC Ki67 labeling index is estimated by counting the number of positive and negative cells. It has not been clarified whether IHC Ki67 estimated using a semiquantitative scoring system has a prognostic value. We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Patients and Methods: We retrospectively identified patients in the Tokai University breast cancer database for whom IHC Ki67 data were available between January 1, 2000 and December 31, 2010. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. Results: Of the 1331 primary breast cancer patients included in the study, In patients with estrogen receptor (ER)-positive and HER2-negative tumors (n = 971), high and intermediate Ki67 scores were associated with poorer relapse-free survival than low Ki67 scores (P <.001 and P = .002, respectively). Furthermore, in the multivariate analyses of this subgroup, progression-free survival (PFS) was significantly longer in patients with low Ki67 scores than in patients with high Ki67 scores (hazard ratio, 0.387; 95% confidence interval, 0.233-0.643; P <.001). In the multivariate analyses, the Ki67 score was not significantly associated with PFS in the ER-positive and HER2-positive, ER-negative and HER2-positive, or ER-negative and HER2- negative subgroups. Conclusion: Our data demonstrated that low, intermediate, and high Ki67 scores have a prognostic value in breast cancer patients with ER-positive and HER2-negative tumors.

Original languageEnglish
Pages (from-to)323-329.e3
JournalClinical Breast Cancer
Volume14
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Breast Neoplasms
Estrogen Receptors
Disease-Free Survival
Multivariate Analysis
Neoplasms
Survival
Databases
Confidence Intervals
Recurrence

Keywords

  • ER
  • Ki67
  • Prognostic marker
  • Proliferation
  • Subgroups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Niikura, N., Masuda, S., Kumaki, N., Xiaoyan, T., Terada, M., Terao, M., ... Tokuda, Y. (2014). Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. Clinical Breast Cancer, 14(5), 323-329.e3. https://doi.org/10.1016/j.clbc.2013.12.013

Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. / Niikura, Naoki; Masuda, Shinobu; Kumaki, Nobue; Xiaoyan, Tang; Terada, Mizuho; Terao, Mayako; Iwamoto, Takayuki; Oshitanai, Risa; Morioka, Toru; Tuda, Banri; Okamura, Takuho; Saito, Yuki; Suzuki, Yasuhiro; Tokuda, Yutaka.

In: Clinical Breast Cancer, Vol. 14, No. 5, 2014, p. 323-329.e3.

Research output: Contribution to journalArticle

Niikura, N, Masuda, S, Kumaki, N, Xiaoyan, T, Terada, M, Terao, M, Iwamoto, T, Oshitanai, R, Morioka, T, Tuda, B, Okamura, T, Saito, Y, Suzuki, Y & Tokuda, Y 2014, 'Prognostic significance of the Ki67 scoring categories in breast cancer subgroups', Clinical Breast Cancer, vol. 14, no. 5, pp. 323-329.e3. https://doi.org/10.1016/j.clbc.2013.12.013
Niikura, Naoki ; Masuda, Shinobu ; Kumaki, Nobue ; Xiaoyan, Tang ; Terada, Mizuho ; Terao, Mayako ; Iwamoto, Takayuki ; Oshitanai, Risa ; Morioka, Toru ; Tuda, Banri ; Okamura, Takuho ; Saito, Yuki ; Suzuki, Yasuhiro ; Tokuda, Yutaka. / Prognostic significance of the Ki67 scoring categories in breast cancer subgroups. In: Clinical Breast Cancer. 2014 ; Vol. 14, No. 5. pp. 323-329.e3.
@article{84f5ad71e49a4c31a76f27646dd22dc0,
title = "Prognostic significance of the Ki67 scoring categories in breast cancer subgroups",
abstract = "We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Our data demonstrated that Ki67 scores have a prognostic value in breast cancer patients with ERpositive and HER2-negative tumors. Background: Immunohistochemical (IHC) expression of Ki67 has a prognostic and predictive value for breast cancer, and the IHC Ki67 labeling index is estimated by counting the number of positive and negative cells. It has not been clarified whether IHC Ki67 estimated using a semiquantitative scoring system has a prognostic value. We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Patients and Methods: We retrospectively identified patients in the Tokai University breast cancer database for whom IHC Ki67 data were available between January 1, 2000 and December 31, 2010. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. Results: Of the 1331 primary breast cancer patients included in the study, In patients with estrogen receptor (ER)-positive and HER2-negative tumors (n = 971), high and intermediate Ki67 scores were associated with poorer relapse-free survival than low Ki67 scores (P <.001 and P = .002, respectively). Furthermore, in the multivariate analyses of this subgroup, progression-free survival (PFS) was significantly longer in patients with low Ki67 scores than in patients with high Ki67 scores (hazard ratio, 0.387; 95{\%} confidence interval, 0.233-0.643; P <.001). In the multivariate analyses, the Ki67 score was not significantly associated with PFS in the ER-positive and HER2-positive, ER-negative and HER2-positive, or ER-negative and HER2- negative subgroups. Conclusion: Our data demonstrated that low, intermediate, and high Ki67 scores have a prognostic value in breast cancer patients with ER-positive and HER2-negative tumors.",
keywords = "ER, Ki67, Prognostic marker, Proliferation, Subgroups",
author = "Naoki Niikura and Shinobu Masuda and Nobue Kumaki and Tang Xiaoyan and Mizuho Terada and Mayako Terao and Takayuki Iwamoto and Risa Oshitanai and Toru Morioka and Banri Tuda and Takuho Okamura and Yuki Saito and Yasuhiro Suzuki and Yutaka Tokuda",
year = "2014",
doi = "10.1016/j.clbc.2013.12.013",
language = "English",
volume = "14",
pages = "323--329.e3",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Prognostic significance of the Ki67 scoring categories in breast cancer subgroups

AU - Niikura, Naoki

AU - Masuda, Shinobu

AU - Kumaki, Nobue

AU - Xiaoyan, Tang

AU - Terada, Mizuho

AU - Terao, Mayako

AU - Iwamoto, Takayuki

AU - Oshitanai, Risa

AU - Morioka, Toru

AU - Tuda, Banri

AU - Okamura, Takuho

AU - Saito, Yuki

AU - Suzuki, Yasuhiro

AU - Tokuda, Yutaka

PY - 2014

Y1 - 2014

N2 - We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Our data demonstrated that Ki67 scores have a prognostic value in breast cancer patients with ERpositive and HER2-negative tumors. Background: Immunohistochemical (IHC) expression of Ki67 has a prognostic and predictive value for breast cancer, and the IHC Ki67 labeling index is estimated by counting the number of positive and negative cells. It has not been clarified whether IHC Ki67 estimated using a semiquantitative scoring system has a prognostic value. We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Patients and Methods: We retrospectively identified patients in the Tokai University breast cancer database for whom IHC Ki67 data were available between January 1, 2000 and December 31, 2010. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. Results: Of the 1331 primary breast cancer patients included in the study, In patients with estrogen receptor (ER)-positive and HER2-negative tumors (n = 971), high and intermediate Ki67 scores were associated with poorer relapse-free survival than low Ki67 scores (P <.001 and P = .002, respectively). Furthermore, in the multivariate analyses of this subgroup, progression-free survival (PFS) was significantly longer in patients with low Ki67 scores than in patients with high Ki67 scores (hazard ratio, 0.387; 95% confidence interval, 0.233-0.643; P <.001). In the multivariate analyses, the Ki67 score was not significantly associated with PFS in the ER-positive and HER2-positive, ER-negative and HER2-positive, or ER-negative and HER2- negative subgroups. Conclusion: Our data demonstrated that low, intermediate, and high Ki67 scores have a prognostic value in breast cancer patients with ER-positive and HER2-negative tumors.

AB - We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Our data demonstrated that Ki67 scores have a prognostic value in breast cancer patients with ERpositive and HER2-negative tumors. Background: Immunohistochemical (IHC) expression of Ki67 has a prognostic and predictive value for breast cancer, and the IHC Ki67 labeling index is estimated by counting the number of positive and negative cells. It has not been clarified whether IHC Ki67 estimated using a semiquantitative scoring system has a prognostic value. We aimed to estimate the usefulness of scoring categories of IHC Ki67 as a prognostic factor for breast cancer subgroups. Patients and Methods: We retrospectively identified patients in the Tokai University breast cancer database for whom IHC Ki67 data were available between January 1, 2000 and December 31, 2010. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. Results: Of the 1331 primary breast cancer patients included in the study, In patients with estrogen receptor (ER)-positive and HER2-negative tumors (n = 971), high and intermediate Ki67 scores were associated with poorer relapse-free survival than low Ki67 scores (P <.001 and P = .002, respectively). Furthermore, in the multivariate analyses of this subgroup, progression-free survival (PFS) was significantly longer in patients with low Ki67 scores than in patients with high Ki67 scores (hazard ratio, 0.387; 95% confidence interval, 0.233-0.643; P <.001). In the multivariate analyses, the Ki67 score was not significantly associated with PFS in the ER-positive and HER2-positive, ER-negative and HER2-positive, or ER-negative and HER2- negative subgroups. Conclusion: Our data demonstrated that low, intermediate, and high Ki67 scores have a prognostic value in breast cancer patients with ER-positive and HER2-negative tumors.

KW - ER

KW - Ki67

KW - Prognostic marker

KW - Proliferation

KW - Subgroups

UR - http://www.scopus.com/inward/record.url?scp=84922653564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922653564&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2013.12.013

DO - 10.1016/j.clbc.2013.12.013

M3 - Article

C2 - 24492237

AN - SCOPUS:84922653564

VL - 14

SP - 323-329.e3

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 5

ER -